In Europe, ruxolitinib and fedratinib are the only JAK2 inhibitors available in local pharmacies. According to trial data, myelofibrosis patients should mostly receive ruxolitinib as first-line treatment and fedratinib in case of failure or intolerance (depending on their profile). Is it possible to reverse the choice of these drugs? Commentary on: Palandri et al. Ruxolitinib after Fedratinib failure in patients with myelofibrosis: a real-world case series. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/ bjh.19654.
机构:
Emory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USAEmory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USA
Puskas, John D.
Steele, Mark
论文数: 0引用数: 0
h-index: 0
机构:
Emory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USAEmory Univ, Sch Med, Div Cardiothorac Surg, Clin Res Unit, Atlanta, GA 30322 USA
机构:
Washington State Univ, Sch Hospitality Business Management, 14204 NE Salmon Creek Ave, Vancouver, WA 98686 USAWashington State Univ, Sch Hospitality Business Management, 14204 NE Salmon Creek Ave, Vancouver, WA 98686 USA
Chen, Chun-Chu
Zou, Suiwen
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Recreat Sport & Tourism, Champaign, IL USAWashington State Univ, Sch Hospitality Business Management, 14204 NE Salmon Creek Ave, Vancouver, WA 98686 USA
Zou, Suiwen
Petrick, James F.
论文数: 0引用数: 0
h-index: 0
机构:
Texas A&M Univ, Dept Recreat Pk & Tourism Sci, College Stn, TX 77843 USAWashington State Univ, Sch Hospitality Business Management, 14204 NE Salmon Creek Ave, Vancouver, WA 98686 USA